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Background: Sciatica is a type of neuropathic pain that is characterised by pain radiating into the leg. It is often
accompanied by low back pain and neurological deficits in the lower limb. While this condition may cause
significant suffering for the individual, the lack of evidence supporting effective treatments for sciatica makes clinical
management difficult. Our objectives are to determine the efficacy of pregabalin on reducing leg pain intensity and
its cost-effectiveness in patients with sciatica.
Methods/Design: PRECISE is a prospectively registered, double-blind, randomised placebo-controlled trial of
pregabalin compared to placebo, in addition to usual care. Inclusion criteria include moderate to severe leg pain
below the knee with evidence of nerve root/spinal nerve involvement. Participants will be randomised to receive
either pregabalin with usual care (n = 102) or placebo with usual care (n = 102) for 8 weeks. The medicine dosage
will be titrated up to the participant’s optimal dose, to a maximum 600 mg per day. Follow up consultations will
monitor individual progress, tolerability and adverse events. Usual care, if deemed appropriate by the study doctor,
may include a referral for physical or manual therapy and/or prescription of analgesic medication. Participants,
doctors and researchers collecting participant data will be blinded to treatment allocation. Participants will be
assessed at baseline and at weeks 2, 4, 8, 12, 26 and 52. The primary outcome will determine the efficacy of
pregabalin in reducing leg pain intensity. Secondary outcomes will include back pain intensity, disability and quality
of life. Data analysis will be blinded and by intention-to-treat. A parallel economic evaluation will be conducted
from health sector and societal perspectives.
Discussion: This study will establish the efficacy of pregabalin in reducing leg pain intensity in patients with
sciatica and provide important information regarding the effect of pregabalin treatment on disability and quality of
life. The impact of this research may allow the future development of a cost-effective conservative treatment
strategy for patients with sciatica.
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Neuropathic pain is a major clinical and epidemiological
problem. It is a result of a lesion or disease affecting the
somatosensory system [1]. The true prevalence of neuro-
pathic pain is difficult to estimate as it encompasses a
variety of disorders [2-4]. Neuropathic pain can result
from a lesion in the central nervous system, such as
cerebrovascular events, multiple sclerosis, spinal cord in-
juries, or a lesion in the peripheral nervous system, such
as painful diabetic neuropathy, or post-herpetic neural-
gia [5,6].
Sciatica is considered a type of neuropathic pain and
can also be referred to as lumbosacral radiculopathy [7].
It is a severe form of low back pain that is characterised
by radiating leg pain below the knee. Clinically, the in-
tense leg pain may be accompanied by neurological
changes of muscle weakness and wasting, sensory
change and diminished reflexes in a nerve root distribu-
tion [8,9]. Sciatica is most commonly caused by lumbar
disc herniation, while non-discogenic causes include
bony or vascular compression, infection or malignancy
[10]. Nearly a third of patients with sciatica will have
persisting symptoms, continuing for up to 2 years [8,11].
Treatment strategies aim at reducing pain and pre-
venting chronic disability, as patients with sciatica have
a reduced quality of life, a longer absence from work
and increased use of health resources compared to
people with localised back pain [12]. Treatment may in-
clude conservative care (such as physical therapies and
advice), pharmacological management and interven-
tional procedures (such as epidural injections and sur-
gery) [8,10,11,13,14].
There are few clinical guidelines on the treatment of
sciatica, reflecting the lack of quality evidence of effect-
ive strategies [15]. We conducted a systematic review of
the evidence for pharmacological management of pain in
patients with sciatica and found that there was no clear
evidence to support the use of non-steroidal anti-
inflammatory drugs, corticosteroids, antidepressants, or
opioid analgesics in the immediate term when compared
to the placebo [16]. When conservative and pharmaco-
logical treatments have been unsuccessful and the leg
pain persists, referral for interventional procedures such
as epidural and foraminal corticosteroid injection or in-
vasive surgery may be considered. These procedures can
be costly, have no guarantee of success and come with
some risk. We have found that early surgery provides a
benefit in the short term but is no better than conserva-
tive care at 1 and 2 years [17,18] and that epidural cor-
ticosteroid injections provide only small, short-term
benefits in pain and disability [11].
One pharmacological strategy that has been successful
in the management of neuropathic pain is the use of
anticonvulsant drugs [5]. Pregabalin is an anticonvulsantwith analgesic and anxiolytic properties. It is a structural
analogue of the neurotransmitter gamma-aminobutyric
acid (GABA) that mediates its actions by binding to
voltage-gated calcium channels in the central nervous
system. Pregabalin is reported to provide rapid initial
pain relief [7] and its lack of metabolic drug interactions
means that pregabalin can be safely co-administered
with other drugs [19]. Pregabalin is known to be effect-
ive in treating post-herpetic neuralgia, painful diabetic
neuropathy and fibromyalgia [20-23] and recently in
neuropathic components of patients with back pain
[24,25] and neck pain [26]. It has also been shown to be
a cost-effective alternative to usual care in patients with
refractory neck pain [27].
Currently there is limited, direct, high quality research
to inform the use of pregabalin in the treatment of
people with sciatica. A small prospective randomised
trial of patients with chronic low back pain (n = 36),
which included some patients with sciatica, suggested
that pregabalin may produce a statistically significant re-
duction in back pain in the short term, but this trial
contained no placebo comparison [25]. Another study
demonstrated patients had a positive response to pre-
gabalin but the study design limited the conclusions
[28]. Observational studies have reported positive results
with pregabalin treatment but these trial designs contain
bias [29,30]. Therefore, while there are some indications
that pregabalin may be a successful treatment for pa-
tients with sciatica, high quality evidence is needed.
Sciatica is a severe, disabling condition with few effect-
ive treatment options. This double-blind, randomised,
placebo-controlled trial aims to determine the efficacy,
safety and cost-effectiveness of pregabalin in reducing
leg pain intensity in patients with sciatica.
Methods/Design
The PRECISE study is a double-blind, randomised,
placebo-controlled trial comparing pregabalin in addition
to usual care, to placebo in addition to usual care for the
treatment of sciatica (Figure 1). Ethics approval has been
granted by the University of Sydney Human Research Eth-
ics Committee (protocol number 15333). The study has
been registered with the Australian and New Zealand
Clinical Trials Registry (ACTRN12613000530729) and
this study protocol follows the SPIRIT statement [31].
Participants and recruitment
Participants will be recruited from patients in the commu-
nity, who have moderate to severe sciatica, and who con-
sult a study general practitioner (GP) or medical specialist
(for example, an orthopaedic surgeon, neurosurgeon,
neurologist or rheumatologist) as an outpatient [32]. GPs
and specialists will be recruited from the Sydney metro-
politan area (Australia) and will be required to hold
Figure 1 PRECISE study design.
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tors (that is, the GP or specialist) will obtain relevant med-
ical history including medication history, and screen the
patient against the eligibility criteria.
Eligible participants will meet all of the following cri-
teria: radiating pain into only one leg below the knee;
nerve root/spinal nerve involvement evidenced by at
least one of the following clinical features: myotomal
weakness, dermatomal sensory deficits, diminished re-
flexes, leg pain radiating in a dermatomal distribution;
leg pain severe enough to cause at least moderate pain
or moderate interference with normal work or daily ac-
tivities over the last week (measured by adaptations of
items 7 and 8 in the short form-36 (SF-36) question-
naire); pain duration of current episode of at least 1
week and up to 1 year; age 18 years or older; and suffi-
cient understanding of the English language or interpret-
ation assistance available to complete the study
treatment and assessments.
Patients will be excluded if they meet any of the fol-
lowing criteria: known or suspected serious spinal path-
ology (such as cauda equina syndrome, or spinal
fracture); pregnant or breastfeeding women, and malesor females planning conception during the 8-week treat-
ment period; scheduled or being considered for spinal
surgery or interventional procedures for sciatica during
the 8-week treatment period; contraindications to
pregabalin (known allergy to pregabalin or significant
renal impairment. Pregabalin is predominantly renally
excreted, so patients with an estimated creatinine clear-
ance of <60 ml/minute will be excluded); or already tak-
ing an anticonvulsant medication, a medication for
neuropathic pain, an antidepressant or a sedative and
unable to cease the medication.
If a patient is eligible, the study doctor will gain in-
formed consent and notify the research team when a
participant has been recruited by telephone, fax, email
or an online system. The doctor will also administer the
study treatment (see ‘Study treatment’ below), including
providing the participant with a sealed medication pack
(see ‘Randomisation and blinding’ below). A researcher
(blinded) will collect baseline data from the participant
in a telephone interview, within 72 hours of the initial
treatment visit with the doctor and before the partici-
pant starts the study medication. Following baseline data
collection, the researcher will inform the participant to
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the study medicine. At this point the participant is con-
sidered to be randomised into the study.
To ensure consistency, the study researchers will train
study doctors in the study design and conduct regular
visits to confirm the protocol is being followed. We also
plan to recruit patients with sciatica who present to
physiotherapists and chiropractors. Registered physio-
therapists and chiropractors will identify potential par-
ticipants and refer them to the research team, who will
then refer potential participants to a study GP for formal
screening. If a patient is eligible and gives their informed
consent, the study GP will then notify the research team
as above and provide the study treatment.Randomisation and blinding
A researcher not involved in participant recruitment or
data collection will generate a randomisation schedule a
priori using a computer-derived random number se-
quence. Study medication will be prepared according to
the randomisation schedule by the central study phar-
macy, then sealed in an opaque medication pack and
supplied to the study doctors. The randomisation sched-
ule will be kept concealed from other researchers. Upon
recruitment, the doctor (blinded) will provide a sealed
medication pack to the participant (blinded), thus ran-
domising the participant to one of two groups: pre-
gabalin with usual care or placebo with usual care.
Placebo capsules will have an identical appearance to the
active pregabalin capsules. The randomisation process
will ensure concealed allocation and blinding of the doc-
tor, participant and outcome assessor.Study treatment
The study treatment will consist of the study medicine
and advice (patient reassurance, staying active and
avoiding bed rest) [33]. Each participant will receive up to
nine weekly face-to-face or telephone consultations with
the study doctor to begin treatment, monitor progress and
adjust the dose of the study medication over the 8-week
treatment period. Specialists who are unable to provide
regular follow up care will refer the participant to theTable 1 PRECISE study medicine dosage
Week Pregabalin (or placebo) dosage
Week 1 1 × 75 mg capsule, twice a day, for 7 day
Week 2 2 × 75 mg capsule, twice a day, for 7 day
Week 3 3 × 75 mg capsule, twice a day, for 7 day
Weeks 4 to 7 4 × 75 mg capsule, twice a day, for 7 day
improvement (0 or 1 out of 10 leg pain f
Week 8 (or after reaching
adequate improvement)
Gradual titration down to cessation, for e
then 1 × 75 mg capsule, twice a day, for
Standard study medication regimen [5].research team who will then arrange for a study GP to
continue the 8-week study treatment.
The starting dose of the study medication, either
pregabalin or placebo, is 75 mg twice daily. This will be
titrated to the participant’s optimal dose, up to a max-
imum of 300 mg twice daily, depending on the patient’s
progress and tolerability at each dose level. In the stand-
ard study dosing regimen (Table 1), we expect a 3-week
titration period, then the maximum tolerated dose for
each participant will be maintained for 4 weeks before
the study medication is titrated down to cessation in the
final (8th) treatment week. The study doctor can amend
the dosage based on a participant’s adequate improve-
ment, defined as a pain rating of 0 or 1 out of 10, for leg
pain, for a minimum of 72 hours, with none or tolerable
side effects. If adequate improvement is achieved before
the 8-week standard treatment regimen is completed,
early titration down to cessation is possible. The max-
imum treatment period is 8 weeks.
In addition to the study medicines, both groups may
receive usual care as deemed appropriate by their study
doctor during the 8-week treatment period. Usual care
may include physical or manual therapies and other an-
algesic medications (except adjuvant analgesics). It is
recommended that the study doctors follow the World
Health Organisation (WHO) pain ladder [34] for analgesic
medication prescription, and refrain from prescribing add-
itional medicines for neuropathic pain or scheduling inter-
ventional procedures. Medicines for neuropathic pain
include antidepressants, selective serotonin and noradren-
aline re-uptake inhibitors, topical lignocaine and gaba-
pentin and other anticonvulsant medications [7]. Also
participants should not take concomitant medication that
could result in an adverse interaction with pregabalin, in-
cluding medicines that might increase the risk of excessive
sedation (for example, benzodiazepines) [35].
Data collection
Data collection will be conducted by the study re-
searchers via telephone, email or online at baseline,
weeks 2, 4, 8, 12, 26 and 52. Data will be collected re-
gardless of participants’ compliance to the study treat-
ment. Data collection by trained study researchers willTotal daily dose
s 150 mg/day
s 300 mg/day
s 450 mg/day
s, maintained over 4 weeks or until adequate
or 72 hours)
600 mg/day
xample 2 × 75 mg capsule, twice a day, for 4 days,
3 days
300 mg/day or
150 mg/day
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lection quality and aid participant retention.
Primary outcome
The primary outcome is leg pain intensity using the Nu-
merical Pain Rating Scale, measured at baseline and weeks
2, 4, 8, 12, 26 and 52. The participants will be asked to rate
their average leg pain over the last 24 hours out of 10,
with zero representing ‘no leg pain’, and 10 representing
the ‘worst pain imaginable’ [36].
Secondary outcomes
The key secondary outcome is the Roland Disability
Questionnaire for Sciatica [18], measured at baseline
and weeks 2, 4, 8, 12, 26 and 52, to assess disability.
The Numerical Pain Rating Scale [36], rated as an
average over the last 24 hours, measured at baseline and
weeks 2, 4, 8, 12, 26 and 52, will assess back pain
intensity.
The SF-12v2 Quality of Life questionnaire [37] will be
used at baseline and weeks 2, 4, 8, 12, 26 and 52, to as-
sess quality of life.
The Global Perceived Effect [38] will be measured at
baseline and weeks 2, 4, 8, 12, 26 and 52, this asks the
participant to compare their leg pain to when this epi-
sode first started. It is measured on a Likert scale, from
a score of −5 (vastly worse) to 0 (unchanged), to +5
(completely recovered).
Work and health utilisation questions will be asked at
weeks 4, 12, 26 and 52. These will report the use of
health services and the number of hours missed from
paid employment because of sciatica, for the cost-
effectiveness analysis.
Other data collected
The use of other analgesic medicines over the previous
week will be collected at baseline. The PainDETECT
questionnaire, which screens for the presence of neuro-
pathic pain [39], will be completed at baseline. Con-
firmed pregnancy will be recorded at 2, 4, 8 and 12
weeks.
Details of adverse events will be collected at 2, 4, 8, 12,
26 and 52 weeks of treatment. The most common ad-
verse effects of pregabalin are dizziness and somnolence
[7]. Any serious adverse events, defined as an event that
is life threatening, results in death, hospitalisation, or
significant disability, will be reported immediately to the
serious adverse events committee (authors, CM, AM
and ROD). The serious adverse events committee will
investigate the relationship between a serious adverse
event and the study medication, and if a potential rela-
tionship is suspected, unblinding to treatment allocation
is permissible. The ethics committee will also be in-
formed of the serious adverse event.Questions will be asked regarding blinding and satis-
faction at week 8. The blinding question will ask the par-
ticipant to guess to which study treatment they were
randomized, that is whether they have been randomized
to pregabalin or placebo, or do not know. The satisfaction
question will ask the participant to rate how satisfied they
felt with the study treatment overall on a 5-point scale
(extremely dissatisfied, dissatisfied, neutral, satisfied or ex-
tremely satisfied).
Adherence to study medication will be documented
through a self-reported daily medication diary and by
counting the returned medicine, compared to the prescribed
regimen as recorded by the study doctor. Participants will
be asked to return unused medicines via a reply-paid post
satchel at the end of the 8-week treatment period.
Data integrity and analysis
The integrity of trial data will be monitored by regularly
scrutinising data files for omissions and errors. We will
perform double data entry of the primary (leg pain) and
key secondary (Roland Disability Questionnaire for Sciatica)
outcomes. Other outcomes will be checked using a risk-
based approach, checking random samples until achiev-
ing a satisfactorily low error rate (for example, <10%).
The source of any inconsistencies will be explored and
resolved. Electronic data will be stored on a secure ser-
ver and paper copies located in a locked cabinet. Data
will only be accessible by researchers and participant
confidentiality will be maintained through secure data
storage, during and post-trial.
Treatment effectiveness analyses will be blinded and
performed on intention-to-treat basis. A two-tailed P-
value <0.05 will be considered statistically significant. Our
primary analysis will be by analysis of covariance, to exam-
ine the effects of treatment on leg pain at week 8, using
the treatment arm, baseline leg pain and symptom dur-
ation as covariates. Similar analyses will be applied to sec-
ondary endpoints. Those will be supported by longitudinal
linear models of leg pain and secondary outcomes, includ-
ing all available post-baseline measurements, with the
baseline measurement and symptom duration as covari-
ates. In the case of significant missing data, sensitivity ana-
lyses will be conducted where reasonable using multiple
imputation [40]. A secondary analysis will assess the pres-
ence of neuropathic pain features, measured by the
PainDETECT questionnaire at baseline as a modifier of
treatment effects.
Economic evaluation will entail a cost-utility analysis
in which the intervention will be assessed in terms of its
incremental cost per quality-adjusted life-year (QALY).
As we do not expect any effect on survival, our QALY
estimates will be based exclusively on health state util-
ities. These will be obtained from measures derived from
the SF-12 and transformed into health state utilities via
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utilities will be averaged out between observations over
the entire duration of follow up of 1 year. The primary
analysis will be conducted from the perspective of the
health sector. The costs of the intervention will be
assessed in terms of costs of medications and consulta-
tions (including follow up visits needed during titration).
Healthcare services and medicines will be valued at
standard rates published by the Australian Government
(the Medical Benefits Scheme standard fees for non-
hospital medical costs, the Pharmaceutical Benefits
Schedule for costs of medicines and Australian Refined
Diagnosis Related Groups cost weights for hospitalisa-
tion costs). Private non-medical healthcare services
(such as physiotherapy) will be valued at standard rates
published by the relevant professional body or third
party payer. An additional analysis will entail a societal
perspective, investigating costs associated with the use of
community services (for example, community hydro-
therapy classes) and work absenteeism because of sciat-
ica. Costs of community services will be based on the
self-reported costs. Costs of absenteeism from paid em-
ployment will be estimated by the number of days ab-
sent from work multiplied by the average wage rate. The
incremental cost per QALY will be estimated as the ratio
of the difference in average cost and QALYs between
intervention arms. Sensitivity analysis will test uncer-
tainty in key parameters such as the selection of cost
weights and statistical variation in quality of life scores.
Sample size
We have calculated the required sample size using a
standard algorithm [41]. The primary outcome is leg pain
at week 8. A sample size of 204 participants (102 per
group) will provide 90% power to detect a difference of
1.5 out of 10 units of leg pain on the Numerical Pain Rat-
ing Scale, assuming a standard deviation of 2.5 [18], a
two-tailed alpha of 0.05, and allowing for 10% of dropouts
and 20% non-compliance. There is no robust evidence for
the smallest worthwhile effect in pain reduction in sciatica
[42]. We have based the sample-size calculation on a
between-group difference of 1.5/10 in leg pain from previ-
ous trials of pregabalin for neuropathic pain [43]. The
sample size also has 90% power to detect a difference be-
tween groups in score of 3 out of 23 at week 8 on our key
secondary outcome, the Roland Disability Questionnaire
for Sciatica. This is based on the between-group difference
(3/23) and standard deviation from one of our previous
sciatica trials (4/23) [18] and the same assumptions taken
for the primary outcome calculation [18].
Modification of the protocol
Any modifications to the protocol that may impact on
the design and conduct of the study will require a formalprotocol amendment. Such amendment will be agreed
upon by the study investigators and approved by the eth-
ics committee prior to implementation. Once approved,
the changes will be communicated to the relevant par-
ties (for example, doctors and participants).Discussion
This paper presents the design and rationale for a
double-blind, placebo-controlled randomised trial com-
paring the efficacy of pregabalin and placebo in addition
to usual care for patients with sciatica. If pregabalin is
shown to be more effective in reducing leg pain com-
pared to placebo, then this study will be one of the first
to provide rigorous evidence of an effective conservative
treatment for the management of sciatica.
The results of this research will definitively assess the
efficacy and cost-effectiveness of pregabalin for the treat-
ment of sciatica and aid in the future development of
clinical management guidelines for patients with sciatica,
as there are, at present, limited effective conservative
treatment options.
We anticipate recruitment to start in the second half
of 2013, with data collection completed by early 2016.
The allocation concealment and double-blind design
minimise bias, while data collection by the study re-
searchers improves data quality and minimises the work-
load placed on recruiting GPs and specialists. This
reduction in doctor workload will allow minimal inter-
ference with their clinical practice and facilitate recruit-
ment. Our team has successfully conducted trials
recruiting from primary care in the Sydney metropolitan
area [44]. This established collaborative network and
trial design will facilitate doctor and patient recruitment
for a sufficient sample size, and aid compliance. Results
of the study will be disseminated via publications and
presentations. The completion of the PRECISE trial will
potentially present a simple, effective and cost-effective
treatment option for patients suffering with sciatica.Competing interests
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